Exploring the market environment of biologics including biosimilar medicines KU Leuven
Following patent expiry and loss of other exclusivity rights, biosimilar medicines can enter the market. Such biosimilar medicines are clinically equivalent to originator biologics with respect to safety and efficacy, but tend to be cheaper due to lower costs of research and development, a faster regulatory approval process and potential improvements in production processes. Hence, they can contribute to sustaining health care expenditure. ...